Tag: FRA:0K9

January 22, 2019

FSD Pharma Strengthens Drug Development with GW Executive

Rupert Haynes and Raza Bokhari of FSD Pharma discuss the company’s pharma initiative, synthetic cannabinoids and extraction methods.
October 22, 2018

FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a NASDAQ Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments, to Create Medical Cannabis Industry Innovator

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE:HUGE) (OTCQB:FSDDF) (FRA:0K9) announced today the signing of a binding letter of...